ASGCT2024: FDA’s Marks on Accelerated Approval, Gene Therapy Costs and More

In a fireside chat at the American Society of Gene & Cell Therapy conference, CBER Director Peter Marks spoke with Takeda’s Kristin Van Goor about how the regulator is approaching the exploding gene therapy space.

Scroll to Top